Key Research Initiatives

The Central Question: Who needs Alpha-1 Antitrypsin therapy beyond those with severe genetic deficiency?

Current Medical Understanding: AAT augmentation therapy is reserved for individuals with severe genetic AATD (typically ZZ genotype) who meet strict lung function criteria.

Our Revolutionary Approach: We're demonstrating that millions of people who don't meet traditional AATD criteria could benefit from AAT therapy as a medication or supplement to prevent disease and improve health.

1. Moderate Deficiency (MZ, SZ, and Other Variants)

• Current status: Often dismissed as "carriers" with no clinical significance
• Our research: Demonstrating that moderate deficiency correlates with: Increased autoimmune disease risk
• Accelerated tissue damage from inflammation
• Higher cancer incidence
• Chronic pain and prolonged inflammatory response
• Initiative goal: Establish treatment protocols for moderate deficiency

1. Normal Genetics with High Inflammatory Burden

• Patients with chronic inflammatory conditions depleting AAT faster than it's produced
• Autoimmune disease patients with elevated neutrophil elastase
• Cancer patients experiencing inflammation-driven progression
• Chronic infection patients with sustained inflammatory response
• Initiative goal: Define when supplementation benefits genetically normal individuals

1. Environmental AAT Depletion

• Smokers and secondhand smoke exposure
• Pollution and occupational exposure
• Chronic medication use affecting AAT levels
• Infectious disease depleting AAT reserves
• Initiative goal: Develop protective supplementation protocols

1. Acquired AAT Deficiency

• Critical illness and sepsis
• Severe COVID-19 and cytokine storm
• Post-surgical inflammation
• Acute inflammatory events
• Initiative goal: Establish acute-use protocols for AAT in critical care

1. Preventive Use in High-Risk Populations

• Family members of AATD patients
• Individuals with genetic risk factors
• Those with multiple autoimmune risk markers
• Patients with precancerous inflammatory conditions
• Initiative goal: Prove prevention is possible before disease manifests

Foundation: Mark Egly's 2020 patent filing identifying excess neutrophil elastase as a major factor in 152 autoimmune diseases.

Research Goals:

• Document neutrophil elastase levels in each autoimmune condition
• Identify tissue-specific damage patterns
• Correlate AAT deficiency with disease severity
• Map inflammatory pathways responsive to AAT

• Small pilot studies in select conditions: Rheumatoid arthritis
• Multiple sclerosis
• Systemic lupus erythematosus
• Inflammatory bowel disease
• Type 1 diabetes
• Measure biomarkers, symptoms, and quality of life
• Establish dosing parameters
• Document safety and tolerability

• Multi-center randomized controlled trials
• Head-to-head comparisons with standard therapies
• Combination therapy studies
• Long-term outcome tracking
• Cost-effectiveness analysis

• Updated treatment guidelines
• Insurance coverage secured
• Widespread physician adoption
• Global availability

Expected Impact: Transform treatment for millions with autoimmune diseases, offering a mechanism-based therapy that addresses root cause rather than just suppressing symptoms.

Key Hypothesis: Chronic inflammation and excess neutrophil elastase contribute to cancer initiation, progression, and metastasis. AAT supplementation may prevent and slow cancer development.

Research Priorities:

• Colon Cancer in IBD: Can AAT reduce cancer incidence in inflammatory bowel disease?
• Lung Cancer in COPD: Does AAT prevent cancer development in chronic lung inflammation?
• Liver Cancer in AATD: Early AAT intervention to prevent hepatocellular carcinoma
• Breast Cancer: AAT's role in inflammation-driven breast cancer
• Leukemia: Intervention role to control childhood and adult Leukemia

• Neutrophil elastase in tumor microenvironment
• AAT blocking cancer cell migration
• Inflammation control preventing metastatic spread
• Combination with standard cancer therapies

• AAT protecting healthy tissue during chemotherapy
• Reducing inflammation-related side effects
• Preserving immune function during treatment
• Improving treatment tolerance and outcomes

Initiative Activities:

• Epidemiological studies of cancer rates in AATD populations
• Animal model studies of AAT in cancer prevention
• Biomarker discovery for identifying high-risk individuals
• Clinical trial design and funding

Foundation: Emerging evidence that Alzheimer's and other neurodegenerative diseases have inflammatory and autoimmune components.

Research Focus Areas:

• AAT levels in Alzheimer's patients vs. healthy controls
• AAT presence in brain plaques and lesions
• Neuroinflammation control through AAT supplementation
• Prevention trials in at-risk populations

• Motor neuron protection from inflammatory damage
• AAT crossing blood-brain barrier
• Slowing disease progression
• Improving quality of life

• Myelin protection from neutrophil elastase
• Reducing attack frequency and severity
• Combination with disease-modifying therapies
• Long-term disability prevention

• Neuronal protection from oxidative stress
• Inflammation control in substantia nigra
• Slowing disease progression
• Improving motor symptoms

Collaborative Efforts:

• Partnering with neurology research centers
• Brain imaging studies
• Biomarker development
• Clinical trial networks

The Challenge: If AAT deficiency damages lungs, what other tissues are vulnerable?

Research Approach:

Bone Marrow and Hematopoiesis

• AAT's role in protecting thrombospondin-1
• Impact on blood cell formation
• Connection to anemia and blood disorders
• Stem cell protection
• Impact on Multiple Myeloma

Cardiovascular System

• Endothelial protection
• Atherosclerosis prevention
• Vascular inflammation control
• Heart tissue protection

Renal System

• Kidney tissue protection
• Glomerular function
• Prevention of nephropathy
• Dialysis patient outcomes

Musculoskeletal System

• Cartilage protection
• Joint health in arthritis
• Bone density and osteoporosis
• Muscle tissue preservation

Gastrointestinal Tract

• Intestinal barrier integrity
• Pancreatic tissue protection
• Liver inflammation control
• Digestive enzyme protection

Reproductive System

• Placental function
• Fertility impacts
• Pregnancy outcomes
• Fetal development

Endocrine System

• Pancreatic islet protection
• Thyroid function
• Adrenal health
• Hormonal regulation

Methodology:

• Tissue banking from AATD patients
• Animal model studies
• Proteomic analysis
• Single-cell sequencing
• Longitudinal patient tracking

Goal: Create the first comprehensive atlas of AAT's protective role throughout the human body.

Current Problem: AATD diagnosis takes an average of 8 years and 4 healthcare providers.

Research Goals:

• Point-of-care testing devices
• Dried blood spot analysis
• At-home testing kits
• Smartphone-based diagnostics
• Rapid genotyping methods

• AAT activity testing (not just quantity)
• Neutrophil elastase burden measurements
• Inflammatory marker panels
• Tissue-specific AAT levels
• Oxidative modification assessment

• Who will progress to severe disease?
• Who will respond to therapy?
• When should treatment begin?
• How to optimize dosing?
• Monitoring treatment effectiveness

• Pre-symptomatic disease identification
• Risk stratification tools
• Prevention target identification
• Family screening protocols

Critical Need: Current plasma-derived AAT cannot meet demand as indications expand.

Research Investment Areas:

• Rice grain expression systems
• Tobacco plant bioreactors
• Moss-based production
• Algae cultivation
• Scale-up and purification

• Transgenic cow milk production
• Transgenic goat milk production
• Chicken egg production
• Safety and efficacy studies
• Regulatory pathway navigation

• CHO cell optimization
• Yeast expression systems
• Bacterial platforms
• Insect cell cultures
• Cell-free synthesis

• AAV vectors for liver transduction
• CRISPR correction of mutations
• Long-term AAT production
• One-time curative approach
• Affordability and access

Expected Outcomes:

• 90% cost reduction
• Unlimited supply
• Global accessibility
• Consistent quality
• Multiple formulation options

Research Question: How can AAT therapy be optimized through combination with other treatments?

Investigation Areas:

• Reducing steroid requirements
• Enhancing biologic effectiveness
• Lowering immunosuppression needs
• Improving remission rates

• Chemotherapy combination studies
• Immunotherapy synergy
• Radiation protection
• Surgical recovery enhancement

• NSAID combination
• Biologic therapy enhancement
• Targeted therapy optimization
• Natural anti-inflammatory synergy

• Diet and nutrition
• Exercise optimization
• Stress reduction
• Sleep quality improvement

1. Patient Registries and Natural History Studies

• Long-term outcome tracking
• Disease progression patterns
• Treatment response documentation
• Real-world evidence generation

1. Health Economics Research

• Cost-effectiveness of early diagnosis
• Economic impact of prevention
• Healthcare utilization patterns
• Quality-adjusted life years (QALYs)

1. Implementation Science

• Physician education effectiveness
• Diagnostic algorithm optimization
• Treatment protocol dissemination
• Barriers to care identification

1. Quality of Life Research

• Patient-reported outcomes
• Functional capacity measures
• Mental health impacts
• Social and economic effects

1. Genetic Epidemiology

• Population prevalence studies
• Genetic modifiers identification
• Ethnic and regional variations
• Gene-environment interactions

Academic Partnerships

• Leading research universities
• Medical schools and teaching hospitals
• Research institutes
• International collaborations

Industry Partnerships

• Pharmaceutical companies
• Biotech firms
• Diagnostic companies
• Medical device manufacturers

Clinical Networks

• Clinical Resource Centers
• Community hospitals
• Private practices
• Telemedicine platforms

Patient Engagement

• Alpha-1 Research Registry
• Patient advisory boards
• Community-based participatory research
• Citizen science initiatives

• Establish research infrastructure
• Launch initial pilot studies
• Build collaborative networks
• Secure research funding
• Publish foundational papers

• Multiple clinical trials initiated
• Biomarker validation studies
• Alternative production milestones
• Guideline update advocacy
• International partnerships

• Clinical trial results published
• Regulatory approvals sought
• Treatment protocols established
• Insurance coverage secured
• Physician education scaled

• Widespread clinical adoption
• Global accessibility achieved
• Prevention programs established
• Continued innovation
• Next-generation therapies

Individual Donors

• Sponsor specific research projects
• Support pilot studies
• Fund patient registries
• Enable researcher training

Corporate Partners

• Research grants and contracts
• In-kind contributions
• Technology access
• Expertise and mentorship

Foundations and Government

• Large-scale funding
• Multi-year commitments
• Infrastructure support
• Collaborative programs

Researchers

• Apply for MEF research grants
• Collaborate with our network
• Share data and findings
• Mentor next generation

Through these key research initiatives, the Mark Egly Foundation will:

• Prove that AAT therapy benefits millions beyond traditional AATD patients
• Prevent autoimmune diseases, cancer, and neurodegeneration before they start
• Protect every tissue and organ system vulnerable to inflammatory damage
• Provide accessible, affordable AAT therapy to everyone who needs it
• Transform medical practice from reactive treatment to proactive prevention

Mark Egly spent decades searching for answers. His discoveries revealed that a single protein—Alpha-1 Antitrypsin—plays a far more crucial role in human health than medicine ever imagined.

Now, through rigorous research and clinical innovation, we're proving that these discoveries can:

• Save millions of lives
• Prevent devastating diseases
• Transform healthcare economics
• Change medicine forever

The research is happening. The evidence is mounting. The future is prevention.

For research partnership inquiries, grant applications, or to support specific initiatives, contact the Mark Egly Foundation Research Program.

Together, we're building the evidence base that will change medicine and save lives for generations to come.